Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy

• Status: Completed
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This double blind randomized trial will compare ibuprofen to acetazolamide for the prevention of acute mountain sickness. These drugs have never been directly compared for efficacy. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Grant S Lipman
• Treatments: Acetazolamide; Ibuprofen

Criteria

Inclusion Criteria:

1. Age 18-65 healthy non-pregnant volunteer

2. Sea-level dwelling (live at low elevation < 4000 ft)

3. Arrange your own transportation to WMRS (Bishop) by Friday evening of study weekend

4. Available for full study duration (Friday PM-Sunday AM)

Exclusion Criteria:

1. Age <18 or >65, Pregnant, Live at altitude >4000 ft

2. Slept at altitude > 4000ft within 1 week of study

3. Allergic to acetazolamide, sulfa drugs, or non-steroidal anti-inflammatories

4. Taking NSAIDs, Acetazolamide, or Corticosteroids 1 week prior to study

5. Medical History of Brain Tumor, increased brain pressure, pseudotumor cerebri, VP shunts, HACE, or HAPE.